logo
Plus   Neg
Share
Email

Constellation Brands Remains Sharply Lower After Initial Drop

After gapping open sharply lower, shares of Constellation Brands, Inc. (STZ) continue to see substantial weakness in late-day trading on Wednesday. Constellation Brands is currently down by 12.3 percent after hitting its lowest intraday level in almost two years.

The initial sell-off by Constellation Brands came after the producer and marketer of beer, wine and spirits reported fiscal third quarter results that exceeded analyst estimates but lowered its full-year earnings guidance.

Constellation Brands reported third quarter adjusted earnings of $2.37 per share on net sales of $1.97 billion, while analysts had expected earnings of $2.06 per share on sales of $1.91 billion.

However, the company forecast full-year adjusted earnings of $9.20 to $9.30 per share compared to its previous guidance for earnings of $9.60 to $9.75 per share.

Constellation Brands said its latest guidance includes costs related to its investment in Canadian cannabis producer Canopy Growth Corp.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
RELATED NEWS
Follow RTT
>